Lirafugratinib
Lirafugratinib is an experimental small-molecule drug from Elevar Therapeutics in phase 2 trials, aimed at FGFR2.
Overview
Lirafugratinib (RLY-4008) is a small-molecule drug developed by Elevar Therapeutics. Its target is FGFR2 (the sponsor names FGFR2). The sponsor states: Oral small-molecule inhibitor of FGFR2. ClinicalTrials.gov describes the intervention as: Lirafugratinib is an oral inhibitor of FGFR2. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07359820, plans to enrol 30 participants with primary completion expected 2027-09. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Lirafugratinib" OR ABSTRACT:"Lirafugratinib" OR TITLE:"RLY-4008" OR ABSTRACT:"RLY-4008") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Lirafugratinib, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentCGT4859
Shares FGFR2 and the tags pipeline, ctgov-ingest.
- TreatmentTYRA-300
Shares FGFR2 and the tags pipeline, ctgov-ingest.
- TreatmentABSK061
Shares FGFR2 and the tags pipeline, ctgov-ingest.
- TreatmentTAR-210
Shares FGFR2 and the tags pipeline, ctgov-ingest.
- TreatmentHMPL-453
Shares FGFR2 and the tags pipeline, ctgov-ingest.
- TreatmentA166
Shares the tags pipeline, ctgov-ingest.
- TreatmentAAA817
Shares the tags pipeline, ctgov-ingest.
- TreatmentABBV-706
Shares the tags pipeline, ctgov-ingest.